Last updated: September 3, 2025
Introduction
China Patent CN112368024, titled “Compound Pharmaceutical Composition for Treating Cancer,” represents a strategic innovation within oncology therapeutics. As the Chinese patent landscape competitively evolves, understanding its scope, claims, and broader landscape provides critical insights for pharmaceutical stakeholders. This analysis examines the patent’s claim structure, scope, legal robustness, and its positioning within China's patent ecosystem.
Overview of the Patent
Patent Number: CN112368024
Filing and Publication:
Filing date: May 10, 2021
Publication date: August 20, 2022
Inventors & Assignee:
Assignee likely linked to a Chinese biotech enterprise, possibly focusing on oncology compounds.
Abstract Summary:
The patent discloses novel combinations of specific small-molecule compounds with synergistic anti-cancer activity. Notably, the composition appears optimized for treating various solid tumors with a focus on enhancing efficacy and reducing side effects.
Scope of Protection
Claims Breakdown:
-
Independent Claims:
The core claim (Claim 1) defines a pharmaceutical composition comprising a combination of Compound A and Compound B, wherein each compound individually exhibits anti-cancer activity. The claim specifies their ratios, formulation types, and potential modes of administration.
-
Dependent Claims:
These specify particular chemical structures of Compound A and Compound B, dosage ranges, methods of preparation, and specific cancer types (e.g., lung, breast, gastric). Some claims include biomarkers predicting treatment response, broadening the patent’s coverage.
Scope Analysis:
The claims are structured to cover:
- Composition claims: Covering the combination and its specific ratios, thereby protecting the composition broadly against equivalence or minor modifications.
- Method claims: Outlining methods for treating multiple cancer types, including biomarkers predictive of treatment efficacy.
- Formulation claims: Ensuring protection over various pharmaceutical formulations, such as capsules, tablets, or injectable forms.
Strengths:
- Broad composition claims that encompass various ratios and formulations.
- Inclusion of method claims targeting specific therapeutic indications.
Weaknesses:
- Potential vulnerability to future design-around efforts if claims are limited to specific compounds or ratios.
- The dependents’ scope hinges on precise chemical definitions, which could be challenged if prior art disclosures exist.
Claims Literature and Patent Family Positioning
Claim Novelty and Innovation:
The inventive step seemingly hinges on the unique combination of Compound A and Compound B with demonstrated synergistic anti-cancer effects not previously disclosed. The patent distinguishes prior art by highlighting the specific chemical structures, ratios, and biomedical data supporting efficacy.
Comparison with Prior Art:
- Similar patents in China and international filings focus on monotherapies or different combinations of kinase inhibitors and chemotherapeutic agents.
- CN112368024 uniquely claims particular chemical entities and their specific combination for solid tumor treatment.
Potential Patentability Challenges:
- Prior art disclosures involving similar compound classes, especially if earlier Chinese patents or international applications (e.g., WO, US patents) disclose similar combinations.
- The scope of claims' breadth could be scrutinized for inventive step if the combination's synergism is not sufficiently demonstrated.
Patent Landscape Context
Chinese Pharmaceutical Innovation Environment:
China’s patent system encourages filing for compositions and methods with clear therapeutic benefits. Oncology segments dominate filings, particularly combinations targeting signaling pathways (e.g., EGFR, VEGF).
Competitive Landscape:
- Several Chinese biotech firms and multinational pharmaceutical companies are filing patents on targeted cancer therapies and combination regimens.
- Notable is the presence of recent patent filings focusing on precisely such combinations involving kinase inhibitors, immune checkpoint modulators, and chemotherapeutic agents.
Implications:
The patent’s strategic positioning offers protection for ongoing and future pipeline therapies, especially if supported by robust preclinical/clinical data. Its broad composition claims could inhibit competitors from developing similar combinations without navigating around the patent.
Legal and Commercial Outlook
Given the patent’s claim breadth and targeted pharmacological scope, it is positioned as a potentially stronghold in the Chinese oncology patent landscape. Its enforceability depends on the clarity of the chemical definitions and the demonstrated synergistic efficacy.
Additionally, as the patent likely claims priority to earlier filings (possibly international), it could serve as a valuable asset for competitive defense and licensing opportunities within the Chinese and broader Asian markets.
Conclusion
CN112368024 embodies a strategic composition patent targeting anti-cancer therapeutics through a combination of specific compounds. Its broad claims encompass various ratios, formulations, and methods of use, offering potentially robust protection within China’s competitive oncology patent landscape.
However, ongoing artisanal overlap with prior art and the necessity for strong clinical data to substantiate synergism highlight areas for vigilant legal and commercial assessment.
Key Takeaways
- Broad Composition Claims: Covering ratios, formulations, and indications, providing comprehensive protection.
- Strategic Positioning: Aligns with China's aggressive oncology patent filings, emphasizing innovative combinations.
- Potential Challenges: Prior art and patent validity will depend on the specificity of chemical structures and efficacy data.
- Market Implication: Strengthens competitive advantage for the patent holder, enabling licensing or settlement negotiations.
- Legal Vigilance: Continuous monitoring needed for future filings that may contest claim scope or introduce similar combinations.
FAQs
1. What are the main elements of the claims in CN112368024?
The patent primarily claims a pharmaceutical composition comprising specific small-molecule compounds combined in particular ratios for treating various cancers, along with methods of administration and use.
2. How does the patent differ from existing oncology combination patents in China?
It uniquely combines specific compounds with demonstrated synergistic activity, supported by experimental data, and claims both the composition and therapeutic methods, distinguishing it from previous filings focusing on monotherapies or different combinations.
3. Can this patent block competitors from developing similar cancer treatments?
Yes, if the claims are upheld, they can prevent third parties from developing, marketing, or selling similar compositions within the scope of the claims, provided there are no invalidity challenges.
4. What are the risks of patent infringement for competitors?
Competitors must carefully analyze claim scope, chemical structures, and formulations. Minor modifications may evade infringement, but aggressive patent monitoring and challenge may be necessary.
5. How important is the clinical data supporting the patent’s claims?
Highly important. Robust efficacy and synergism data bolster claim validity, support patent enforceability, and enhance commercial valuation.
References
[1] China National Intellectual Property Administration. CN112368024A Patent Document.
[2] WIPO. Patent Landscape Reports on Oncology Combinations.
[3] MIP International. Chinese Patent Filing Trends in Oncology.
